This HTML5 document contains 95 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00180/identifier/pharmgkb/
dctermshttp://purl.org/dc/terms/
n30http://linked.opendata.cz/resource/AHFS/
n12http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n8http://linked.opendata.cz/resource/mesh/concept/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00180/identifier/pubchem-compound/
n16http://linked.opendata.cz/resource/drugbank/dosage/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00180/identifier/pubchem-substance/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00180/identifier/kegg-drug/
n22http://bio2rdf.org/drugbank:
n21http://linked.opendata.cz/resource/drugbank/drug/DB00180/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n24http://linked.opendata.cz/resource/drugbank/drug/DB00180/identifier/national-drug-code-directory/
n27http://www.rxlist.com/cgi/generic/
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n13http://linked.opendata.cz/resource/drugbank/medicinal-product/
n7http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n20http://linked.opendata.cz/resource/drugbank/drug/DB00180/identifier/chemspider/
n3http://linked.opendata.cz/ontology/drugbank/
n15http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
n17http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00180/identifier/chebi/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/ontology/sukl/drug/
n19http://linked.opendata.cz/resource/atc/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00180/identifier/wikipedia/

Statements

Subject Item
n2:DB00180
rdf:type
n3:Drug
n3:description
Flunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid often prescribed as treatment for allergic rhinitis. The principle mechanism of action of flunisolide is to activate glucocorticoid receptors. It also has anti-inflammatory action.
n3:dosage
n16:271B52DF-363D-11E5-9242-09173F13E4C5 n16:271B52DD-363D-11E5-9242-09173F13E4C5 n16:271B52DE-363D-11E5-9242-09173F13E4C5
n3:group
approved investigational
n3:halfLife
1.8 hours
n3:indication
For the maintenance treatment of asthma as a prophylactic therapy.
n3:manufacturer
n12:271B52CD-363D-11E5-9242-09173F13E4C5 n12:271B52CE-363D-11E5-9242-09173F13E4C5 n12:271B52D1-363D-11E5-9242-09173F13E4C5 n12:271B52D2-363D-11E5-9242-09173F13E4C5 n12:271B52CF-363D-11E5-9242-09173F13E4C5 n12:271B52D0-363D-11E5-9242-09173F13E4C5 n12:271B52D3-363D-11E5-9242-09173F13E4C5
owl:sameAs
n11:DB00180 n22:DB00180
dcterms:title
Flunisolide
adms:identifier
n6:Flunisolide n20:74144 n21:DB00180 n23:5106 n24:0456-0672-99 n25:PA449661 n26:D00324 n28:82153 n29:46507894
n3:mechanismOfAction
Flunisolide is a glucocorticoid receptor agonist. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Flunisolide binds to plasma transcortin, and it becomes active when it is not bound to transcortin.
n3:packager
n12:271B52CB-363D-11E5-9242-09173F13E4C5 n12:271B52CC-363D-11E5-9242-09173F13E4C5 n12:271B52C9-363D-11E5-9242-09173F13E4C5 n12:271B52CA-363D-11E5-9242-09173F13E4C5 n12:271B52C7-363D-11E5-9242-09173F13E4C5 n12:271B52C8-363D-11E5-9242-09173F13E4C5 n12:271B52C5-363D-11E5-9242-09173F13E4C5 n12:271B52C6-363D-11E5-9242-09173F13E4C5 n12:271B52C3-363D-11E5-9242-09173F13E4C5 n12:271B52C4-363D-11E5-9242-09173F13E4C5 n12:271B52C1-363D-11E5-9242-09173F13E4C5 n12:271B52C2-363D-11E5-9242-09173F13E4C5 n12:271B52C0-363D-11E5-9242-09173F13E4C5
n3:synonym
Flunisolidum Flunisolide anhydrous Flunisolida
n18:hasAHFSCode
n30:52-08-08
n3:proteinBinding
Approximately 40% after oral inhalation
n3:synthesisReference
Richard E. Jones, Jacquelyn A. Smithers, "Process for preparing flunisolide." U.S. Patent US4273710, issued July, 1965.
n7:hasConcept
n8:M0051093
foaf:page
n15:flunisolide-spray.html n17:aer1009.shtml n27:flunisolide.htm
n3:IUPAC-Name
n4:271B52E4-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B52EA-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B52E9-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B52E6-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B52E7-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B52E8-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B52E2-363D-11E5-9242-09173F13E4C5 n4:271B52FA-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B52FC-363D-11E5-9242-09173F13E4C5 n4:271B52E3-363D-11E5-9242-09173F13E4C5 n4:271B52E0-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B52E1-363D-11E5-9242-09173F13E4C5
n18:hasATCCode
n19:R03BA03 n19:R01AD04
n3:H-Bond-Acceptor-Count
n4:271B52F0-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B52F1-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B52EB-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B52EC-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B52EE-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B52ED-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B52EF-363D-11E5-9242-09173F13E4C5
n3:absorption
Absorbed rapidly
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
3385-03-3
n3:containedIn
n13:271B52DB-363D-11E5-9242-09173F13E4C5 n13:271B52DC-363D-11E5-9242-09173F13E4C5 n13:271B52D9-363D-11E5-9242-09173F13E4C5 n13:271B52DA-363D-11E5-9242-09173F13E4C5 n13:271B52D7-363D-11E5-9242-09173F13E4C5 n13:271B52D8-363D-11E5-9242-09173F13E4C5 n13:271B52D5-363D-11E5-9242-09173F13E4C5 n13:271B52D6-363D-11E5-9242-09173F13E4C5 n13:271B52D4-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B52F6-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B52F8-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B52F9-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B52FB-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B52F5-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B52F4-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B52F7-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B52E5-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B52F2-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B52F3-363D-11E5-9242-09173F13E4C5